重症成人镇痛镇静优化的药物基因组学精准医学方法
本文综述了重症监护中药物基因组学变异作为镇痛镇静药物反应重要决定因素的证据,指出全基因组关联研究和候选基因研究提示依据个体遗传背景、环境适应及患者和药物相关因素定制镇痛镇静方案可最大化疗效并减少伤害。但ICU药物基因组学研究数量仍少,尚无前瞻性研究利用药物基因组学数据优化重症患者镇痛镇静治疗,当前推荐基于外部效度较低的对照研究。
要点
- 药物基因组学变异是ICU镇痛镇静药物反应的重要决定因素。
- 个体化镇痛镇静需综合考虑遗传、环境及患者和药物因素。
- 目前尚无前瞻性研究用药物基因组学数据优化ICU镇痛镇静。
核心结论
- 药物基因组学精准医学方法有望优化ICU患者镇痛镇静的舒适性与安全性并改善预后。
研究设计与样本
- 本文为综述,描述聚焦于优化个体ICU患者镇痛镇静治疗的精准医学方法。
主要发现
- 全基因组关联和候选基因研究发现药物基因组学变异是ICU镇痛镇静药物反应的重要决定因素。
- 目前ICU药物基因组学研究数量仍少,尚无前瞻性研究利用药物基因组学数据优化重症患者镇痛镇静治疗。
- 当前ICU疼痛和躁动治疗推荐基于外部效度较低的对照研究,未考虑影响反应的药物基因组学因素。
临床怎么用
- 临床可考虑将药物基因组学因素纳入ICU镇痛镇静个体化用药决策以优化舒适与安全。
- 利用大型标准化数据集可帮助评估个体镇痛和/或镇静治疗的获益与风险。
局限性
- ICU药物基因组学研究数量仍少,尚无前瞻性研究验证药物基因组学指导的镇痛镇静优化。
- 当前治疗推荐基于外部效度较低的对照研究,未考虑药物基因组学因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Precision medicine is a growing field in critical care. Research increasingly demonstrated pharmacogenomic variability to be an important determinant of analgesic and sedative drug response in the intensive care unit (ICU). Genome-wide association and candidate gene finding studies suggest analgesic and sedatives tailored to an individual's genetic makeup, environmental adaptations, in addition to several other patient- and drug-related factors, will maximize effectiveness and help mitigate harm. However, the number of pharmacogenetic studies in ICU patients remains small and no prospective studies have been published using pharmacogenomic data to optimize analgesic or sedative therapy in critically ill patients. Current recommendations for treating ICU pain and agitation are based on controlled studies having low external validity, including the failure to consider pharmacogenomic factors affecting response. Use of a precision medicine approach to individualize pharmacotherapy focused on optimizing ICU patient comfort and safety may improve the outcomes of critically ill adults. Additionally, benefits and risks of analgesic and/or sedative therapy in an individual may be informed with large, standardized datasets. The purpose of this review was to describe a precision medicine approach focused on optimizing analgesic and sedative therapy in individual ICU patients to optimize clinical outcomes and reduce safety concerns.
引用
- Dzierba AL, Stollings JL, Devlin JW, et al. A pharmacogenetic precision medicine approach to analgesia and sedation optimization in critically ill adults. Pharmacotherapy. 2023. PMID: 36680385. doi:10.1002/phar.2768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。